Quality of life · general population
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · general population
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Resource use and costs · general population
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neovascular AMD · general population
It is very uncertain whether vitamin E changes neovascular AMD compared with placebo (very low certainty).
1 finding from 1 review
Geographic atrophy · general population
It is very uncertain whether vitamin E changes geographic atrophy compared with placebo (very low certainty).
1 finding from 1 review
Quality of life · general population
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects (AE) · general population
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Resource use and costs · general population
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any AMD · general population
Beta‐carotene showed no clear difference in any AMD compared with placebo (high certainty).
1 finding from 1 review
Progression to late AMD (neovascular AMD, geographic atrophy or both) · general population
Beta‐carotene showed no clear difference in late AMD (either neovascular AMD or geographic atrophy or both) compared with placebo (moderate certainty).
1 finding from 1 review
IOP increase of ≥ 5 mmHg within 2 hours · people with glaucoma receiving LTP
1 finding from 1 review
IOP increase of ≥ 10 mmHg within 2 hours · people with glaucoma receiving LTP
Medication probably leads to lower IOP increase of ≥ 10 mmHg within 2 hours compared with placebo (moderate certainty).
1 finding from 1 review
Mean change in IOP from pre‐LTP within 2 hours · people with glaucoma receiving LTP
1 finding from 1 review
IOP increase of ≥ 5 mmHg between 2 and 24 hours · people with glaucoma receiving LTP
Medication may leads to lower IOP increase of ≥ 5 mmHg between 2 and 24 hours compared with placebo (low certainty).
1 finding from 1 review
IOP increase of ≥ 10 mmHg between 2 and 24 hours · people with glaucoma receiving LTP
It is very uncertain whether medication changes IOP increase of ≥ 10 mmHg between 2 and 24 hours compared with placebo (very low certainty).
1 finding from 1 review
Mean change in IOP from pre‐LTP between 2 and 24 hours · people with glaucoma receiving LTP
1 finding from 1 review
Adverse events ‐ conjunctival blanching during study period · people with glaucoma receiving LTP
1 finding from 1 review
Change in BCVA (lower logMAR indicate better vision) · People aged 50 years or older with age‐related macular degeneration
1 finding from 1 review
Onset and progression of AMD · People aged 50 years or older with age‐related macular degeneration
1 finding from 1 review
Adverse outcomes · People aged 50 years or older with age‐related macular degeneration
1 finding from 1 review